Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.

ABSTRACT:

Background

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis. A common reason for being classified as unresectable is advanced loco-regional disease.A review of the literature indicates that almost nine hundred patients with pancreatic cancer have received regional chemotherapy in the last 15 years. Phase I studies have shown regional administration of chemotherapy to be safe. The average reported response rate was approximately 26%. The average 1-year survival was 39%, with an average median survival of 9 months. Of the patients that experienced a radiographic response to therapy, 78 (78/277, 28%) pati

SUBMITTER: Davis JL 

PROVIDER: S-EPMC3118359 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature